Researchers with the ECOG-ACRIN Cancer Research Group will present a wide range of abstracts at the annual meeting of the American Society of Clinical Oncology (ASCO)

Although the S1216 study missed its primary endpoint, it also showed an unprecedented median overall survival of 70 months in the control arm, the highest ever reported for these patients on a non-intensified androgen deprivation therapy arm

This generous donation will specifically be allotted to further research by under-represented minority investigators in the area of ovarian cancer, genetic testing, and the extension of genetic testing to family members

New subcommittee will provide a forum for advocating for these communities and engaging them in NRG research

Reversing resistance to PD-1 inhibitors with combination immunotherapy in patients with advanced melanoma

The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) is more than halfway to its recruiting goal of 128,905 participants

Analysis concludes that homologous recombination repair mutant type (HRRmt) is prognostic of progression-free survival and predictive for activity of olaparib when compared to the standard of care, platinum-based chemotherapy for women with recurrent platinum-sensitive ovarian cancer

The addition of atezolizumab prior to and concurrently given with chemoradiation treatment is safe for women with node-positive, locally advanced cervical cancer

Updated results from the Phase III OlympiA trial showed that olaparib (Lynparza) significantly improved overall survival in patients with high-risk HER2-negative early breast cancer and germline BRCA mutations